Mathivanan Rajagopal

Head - Research & Development at Rising Pharmaceuticals

Mathivanan Rajagopal began their work experience as a Team Leader at Strides Arcolab Limited in 2004, where they managed product development and led formulation development teams. Mathivanan then joined Malaysian Pharmaceutical Industries Sdn. Bhd. in 2012 as the R&D Incharge, overseeing formulation, analytical, and technology transfer activities. During their tenure, they increased the R&D team size and ensured efficient utilization of resources. In 2016, Rajagopal joined GSK Consumer Healthcare India as a Senior Research Scientist, managing a direct team and global teams for various projects. Mathivanan was responsible for concept testing, product identification, and other aspects of the research process. Currently, Rajagopal is the Head of Research & Development at Rising Pharmaceuticals, a role they assumed in 2021.

Mathivanan Rajagopal completed a Post Graduate certificate in Business Administration and Management, General from the Indian Institute of Management Tiruchirappalli from 2020 to 2021. Prior to that, they obtained an M.pharm degree in Quality assurance from Annamalai University from 2002 to 2004. Mathivanan had also earned a B.Pharmacy degree in Pharmaceutical Sciences from Tamil Nadu Dr. M.G.R. Medical University, Chennai from 1997 to 2000. Before their university education, they completed their HSE from Swamy Shivananda Higher Secondary School between 1995 and 1997. Additionally, Mathivanan has certifications in various areas such as Creating Your Personal Brand, Designing a Presentation, Asserting Yourself, an Empowered Choice, Delivering an Authentic Elevator Pitch, Increase Visibility to Advance Your Career, Recharge Your Energy for Peak Performance, and Six Sigma: Black Belt from LinkedIn, obtained in different months and years in 2020. There is also a mention of an M.Pharmacy degree from Annamalai University, although no specific dates are provided.

Links

Timeline

  • Head - Research & Development

    June, 2021 - present